Bionomics begins manufacture of anti-cancer stem cell treatment

04/25/2013 | Pharmaceutical Business Review Online

Bionomics has begun production work for BNC101, its stem cell therapy candidate for cancer, at its U.K. plant in Slough. "The start of manufacturing activities for BNC101 signals a significant step towards clinical trials," said Bionomics' CEO and managing director, Dr. Deborah Rathjen. The firm expects clinical studies to start next year.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
PRINCIPAL ENGINEER - R&D - 14000009CP
Abbott
Chicago, IL